94 related articles for article (PubMed ID: 34671210)
1. Low-density lipoprotein receptor-related protein 6 (LRP6) rs10845498 polymorphism is associated with a decreased risk of non-small cell lung cancer.
Deng D; Zhang Y; Bao W; Kong X
Int J Med Sci; 2014; 11(7):685-90. PubMed ID: 24843317
[TBL] [Abstract][Full Text] [Related]
2. Targeting LRP6: A new strategy for cancer therapy.
Xue W; Zhu B; Zhao K; Huang Q; Luo H; Shou Y; Huang Z; Guo H
Pharmacol Res; 2024 Jun; 204():107200. PubMed ID: 38710241
[TBL] [Abstract][Full Text] [Related]
3. The effects of high-intensity interval training and Iranian propolis extract on serum levels of TRPV4 and CYP2E1 proteins in patients with nonalcoholic fatty liver.
Irandoust K; Gholamhosseini M; Samimi R; Dergaa I; Ben Saad H; Taheri M
Tunis Med; 2024 Jan; 102(1):19-25. PubMed ID: 38545725
[TBL] [Abstract][Full Text] [Related]
4. Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk.
Pierzynski JA; Hildebrandt MA; Kamat AM; Lin J; Ye Y; Dinney CP; Wu X
J Urol; 2015 Dec; 194(6):1771-6. PubMed ID: 26173102
[TBL] [Abstract][Full Text] [Related]
5. Novel variant in LRP6 associated with unusual and severe clinical presentation: Case report.
Previdi A; Dubourg C; Cormier Daire V; Fradin M; Collet C
Clin Genet; 2024 Jun; 105(6):666-670. PubMed ID: 38385987
[TBL] [Abstract][Full Text] [Related]
6. Whole-Exome Sequencing (WES) Reveals Novel Sex-Specific Gene Variants in Non-Alcoholic Steatohepatitis (MASH).
Wei J; Wu BJ; Daoud SS
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540416
[TBL] [Abstract][Full Text] [Related]
7. Genetic Variants in the SAMM50 Gene Create Susceptibility to Nonalcoholic Fatty Liver Disease in a Chinese Han Population.
Chen L; Lin Z; Jiang M; Lu L; Zhang H; Xin Y; Jiang X; Xuan S
Hepat Mon; 2015 Oct; 15(10):e31076. PubMed ID: 26587038
[TBL] [Abstract][Full Text] [Related]
8. Perturbation of Wnt/β-catenin signaling and sexual dimorphism in non-alcoholic fatty liver disease.
Yeh MM; Shi X; Yang J; Li M; Fung KM; Daoud SS
Hepatol Res; 2022 May; 52(5):433-448. PubMed ID: 35120274
[TBL] [Abstract][Full Text] [Related]
9. Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19.
Bai Y; Zhang J; Li J; Liao M; Zhang Y; Xia Y; Wei Z; Dai Y
Br J Pharmacol; 2024 Jun; ():. PubMed ID: 38839561
[TBL] [Abstract][Full Text] [Related]
10. Examining the expression of low-density lipoprotein receptor (
Behrouj H; Erfani M; Mokarram P
Mol Biol Res Commun; 2024; 13(2):85-88. PubMed ID: 38504780
[TBL] [Abstract][Full Text] [Related]
11. Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1.
Wu M; Tie M; Hu L; Yang Y; Chen Y; Ferguson D; Chen Y; He A
Biochem Biophys Res Commun; 2024 Apr; 702():149655. PubMed ID: 38340654
[TBL] [Abstract][Full Text] [Related]
12. LRP6 Receptor Plays Essential Functions in Development and Human Diseases.
Alrefaei AF; Abu-Elmagd M
Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052459
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches.
Mahmoudi SK; Tarzemani S; Aghajanzadeh T; Kasravi M; Hatami B; Zali MR; Baghaei K
Eur J Med Res; 2024 Mar; 29(1):190. PubMed ID: 38504356
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol in Liquor Exacerbates Alcoholic Liver Injury with a Reduced Therapeutic Effect in Mice: An Unsupervised Herbal Wine Habit Is Risky.
Zhang S; Xu Y; Ye M; Ye W; Xiao J; Zhou H; Zhang W; Shu Y; Huang Y; Chen Y
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432440
[TBL] [Abstract][Full Text] [Related]
15.
Chen LJ; Lin XX; Guo J; Xu Y; Zhang SX; Chen D; Zhao Q; Xiao J; Lian GH; Peng SF; Guo D; Yang H; Shu Y; Zhou HH; Zhang W; Chen Y
Int J Biol Sci; 2021; 17(14):3936-3953. PubMed ID: 34671210
[No Abstract] [Full Text] [Related]
16. The LRP6 functional mutation rs2302685 contributes to individual susceptibility to alcoholic liver injury related to the Wnt/β-catenin-TCF1-CYP2E1 signaling pathway.
Xu Y; Chen D; Lin XX; Zhao Q; Guo J; Chen LJ; Zhang W; Xiao J; Lian GH; Peng SF; Guo D; Yang H; Obianom O; Shu Y; Chen Y
Arch Toxicol; 2019 Jun; 93(6):1679-1695. PubMed ID: 30976847
[TBL] [Abstract][Full Text] [Related]
17. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
Lu W; Lin C; King TD; Chen H; Reynolds RC; Li Y
Cell Signal; 2012 Dec; 24(12):2291-6. PubMed ID: 22820499
[TBL] [Abstract][Full Text] [Related]
18. Role and mechanisms of action of microRNA‑21 as regards the regulation of the WNT/β‑catenin signaling pathway in the pathogenesis of non‑alcoholic fatty liver disease.
Wang XM; Wang XY; Huang YM; Chen X; Lü MH; Shi L; Li CP
Int J Mol Med; 2019 Dec; 44(6):2201-2212. PubMed ID: 31638173
[TBL] [Abstract][Full Text] [Related]
19. Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.
Go GW
Nutrients; 2015 Jun; 7(6):4453-64. PubMed ID: 26046396
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
